The World Health Organization (WHO) has announced the availability of artemether-lumefantrine, a combination drug specifically formulated for newborns and infants weighing up to five kilograms. This development addresses a critical need in treating malaria within regions of Africa where the disease is endemic. Approximately 30 million infants are born annually in these areas, and the WHO estimates a significant portion have previously received drugs designed for older children.
This practice has been associated with an elevated risk of adverse side effects. The new drug offers a targeted solution, minimizing potential complications. Alongside existing vaccines, which provide some protection against mosquito-borne malaria in young children, the artemether-lumefantrine drug represents a vital advancement in infant treatment.
“Malaria has been stealing children from their parents, communities and health, wealth and hope for centuries,” stated WHO Director-General Tedros Adhanom Ghebreyesus. The WHO’s initiative aims to bridge the gap in treatment options for infants, contributing to improved health outcomes and reducing the devastating impact of malaria within vulnerable populations. The drug’s availability underscores the organization’s ongoing commitment to combating this persistent global health challenge.
Topics: #who #drug #infants
This is a significant step forward in protecting vulnerable infants from malaria.
What are the potential long-term effects of using this drug on infants?